Keywords: Novartis, Signifor, Cushing's disease, EU approval

First Cushing's drug, Novartis' Signifor, approved in the EU

Article | 25 April 2012

Print This

The European Commission has approved Swiss drug major Novartis’ (NOVN: VX) Signifor (pasireotide) for the treatment of adult patients ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in